Leucid Bio: Funding, Investors & Team (Oct 2026)
Leucid Bio is a pioneering biotech company developing cell therapies for refractory cancers, especially solid tumors. Leucid was founded to translate 20 years of King's College London (King's) research in the CAR-T field and is led by a highly experienced management team with both scientific and commercial expertise. As part of Leucid's ongoing relationship with King's, it benefits from exclusive access to and resources from the deep scientific, clinical, and manufacturing expertise of Dr. Maher and his academic team of immuno-oncology experts.
Leucid Bio has raised $15.9M across 1 funding round on record, the most recent a Series A of $15.9M announced in Oct 2021.
That round is above the $8.4M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Leucid Bio Company Profile and Key Stats
Latest funding round on record: Oct 2021.
Leucid Bio Funding Rounds
Leucid Bio Founders and Leadership Team
Contact details for the Leucid Bio team: 1 of 1 has an email address on file.
Start 14-day free trial →Leucid Bio Funding Compared to Other Biotechnology Startups
Leucid Bio's latest round of $15.9M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Leucid Bio in Biotechnology and London
Companies Similar to Leucid Bio
Microbiotica develops treatments involving live bacteria found in the human microbiome, aiming to identify…
OMass Technologies is a drug discovery company exploiting novel mass spectrometry platforms to develop…
HydRegen, based in Oxford, UK, is a biotech firm that offers eco-friendly alternatives for the production of…
R1 Therapeutics is a clinical‑stage biopharmaceutical company focused on discovering and developing new drug…
The perfect package for any general surgical trainee or resident. Progress from beginner to advanced surgical…
Argonaute RNA company research projects build on existing intellectual property.
An innovative C elegans company that serves the biotech, nutrition, and other industries and fields of study…
ViaNautis, previously known as SomaServe, was established in 2018 as a separate entity from UCL under the…
Alchemab is harnessing the naturally protective power of patient antibodies to keep people free of…
Biodexa Pharmaceuticals is an international specialty pharmaceutical company focused on oncology and other…
Concert Bio helps businesses create optimal microbial communities.
RQ Bio is a biotechnology company that develops long-acting monoclonal antibodies against seasonal influenza…
Leucid Bio Funding FAQs
What does Leucid Bio do?
Leucid Bio is a pioneering biotech company developing cell therapies for refractory cancers, especially solid tumors. Leucid was founded to translate 20 years of King's College London (King's) research in the CAR-T field and is led by a highly experienced management team with both scientific and commercial expertise. As part of Leucid's ongoing relationship with King's, it benefits from exclusive access to and resources from the deep scientific, clinical, and manufacturing expertise of Dr. Maher and his academic team of immuno-oncology experts.
How much funding has Leucid Bio raised?
Leucid Bio has raised $15.9M across 1 round on record. The most recent is a Series A of $15.9M announced in Oct 2021.
When did Leucid Bio last raise funding?
Leucid Bio's most recent funding round on record is a Series A of $15.9M, announced in Oct 2021.
Who is the CEO of Leucid Bio?
Artin Moussavi is listed as CEO at Leucid Bio.
Where is Leucid Bio headquartered?
Leucid Bio is based in London, England, United Kingdom.
How many employees does Leucid Bio have?
Leucid Bio is in the 11-50 employee band.
How does Leucid Bio's funding compare to other Biotechnology startups?
Leucid Bio's latest round of $15.9M is above the $8.4M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Leucid Bio Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Leucid Bio is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.